Patenting livestock microbiome tech: trends and takeaways
27-10-2022
Will Big Pharma get the bug for microbiome therapies?
06-05-2020
Alpha Tauri 3D Graphics / Shutterstock.com
Protecting new and inventive innovations in this increasingly crowded area is essential, explains Ine Vanderleyden of Mewburn Ellis.
Our body hosts trillions of microorganisms that live symbiotically on and within the human body. This ‘microbiome’ is essential to our health and microbial imbalance or dysbiosis increases the susceptibility to many diseases, including inflammatory bowel disease (IBD), liver disease, atherosclerosis, and other severe pathologies. Given its central role in health and disease, the microbiome has become a prominent therapeutic target.
Microbial consortia
In two early proof-of-concept studies, researchers were able to restore microbiome balance in patients with IBD and Clostridum Difficile infection using Fecal Microbiota Transplantation (FMT), essentially replacing the ‘bad’ bacteria with ‘good’ ones from healthy donors. These initial studies provided an impetus for the development of therapeutic compositions that contain microorganisms, with many targeting the gut.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Microbial, microbiome, consortia, patents, European patent office, inflammatory bowel disease (IBD), liver disease, atherosclerosis, T cells
